Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCL

By Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA - January 13, 2023

Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, of the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, discusses the recent New England Journal of Medicine publication on a phase II trial of glofitamab, a bispecific antibody, in patients with diffuse large B-cell lymphoma.

Advertisement
Editorial Board

Advertisement